EUVIMEDEUVIMED entdecken
Open Access

Patient Survival and Its Relation to Tumor Absorbed Dose in [ 177 Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors

Carl Fredrik Warfvinge, Selma Curkic Kapidzic, Johan Gustafsson, Lovisa Jessen, Johanna Svensson, Anna Sundlöv, Katarina Sjögreen Gleisner

Journal of Nuclear Medicine · 06.08.2026 · jnumed.125.271439

DOI: 10.2967/jnumed.125.271439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.08.2026. Verfasst von Carl Fredrik Warfvinge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden; carlfredrik.warfvinge@med.lu.se. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Absorption, Radiation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsAbsorption, RadiationHumansFemaleMaleMiddle AgedRadiotherapy DosageAgedAdultTreatment Outcome

Stichwörter der Autor:innen

dosimetryendocrineneuroendocrine tumoroncology

Substanzen

Octreotidelutetium Lu 177 dotatateOrganometallic Compounds

Autor:innen und Institutionen

  • Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden; carlfredrik.warfvinge@med.lu.se.
  • Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Medical Radiation Physics, Lund, Lund University, Lund, Sweden; and.
  • Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Zitieren

APA

Warfvinge, C. F., Kapidzic, S. C., Gustafsson, J., Jessen, L., Svensson, J., Sundlöv, A., & Sjögreen Gleisner, K. (2026). Patient Survival and Its Relation to Tumor Absorbed Dose in [ 177 Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors. Journal of Nuclear Medicine, jnumed.125.271439. https://doi.org/10.2967/jnumed.125.271439

Vancouver

Warfvinge CF, Kapidzic SC, Gustafsson J, Jessen L, Svensson J, Sundlöv A, et al. Patient Survival and Its Relation to Tumor Absorbed Dose in [ 177 Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors. Journal of Nuclear Medicine. 2026:jnumed.125.271439. doi:10.2967/jnumed.125.271439

BibTeX
@article{Warfvinge2026,
  author = {Warfvinge, Carl Fredrik and Kapidzic, Selma Curkic and Gustafsson, Johan and Jessen, Lovisa and Svensson, Johanna and Sundlöv, Anna and Sjögreen Gleisner, Katarina},
  title = {Patient Survival and Its Relation to Tumor Absorbed Dose in [ 177 Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.125.271439},
  doi = {10.2967/jnumed.125.271439}
}
Kostenlos starten →